FDA Approves New Bladder Cancer Immunotherapy Treatment

Adults with BCG-unresponsive bladder cancer now have access to Anktiva, which may help avoid surgical tumor removal.

Updated on Oct. 29, 2026 in Cancer

Isometric editorial illustration of clean, blank medical vials sitting on a sterile laboratory surface, representing new bladder cancer treatment. — The FDA has granted approval for Anktiva, a new immunotherapy treatment for patients with specific non-muscle invasive bladder cancer, offering a potential alternative to surgery. AI Illustration. Upload story photo >

Live Poll

Should the FDA use evidence from related diseases to approve new treatments faster?

The FDA has expanded its approval of the drug Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that is unresponsive to BCG treatment. This immunotherapy approach is administered alongside Bacillus Calmette-Guérin to help patients avoid standard surgical interventions.

Why it matters

For patients with this specific form of bladder cancer, finding alternatives to invasive surgery is a critical clinical goal. The FDA based this decision on biological similarities between papillary-only disease and carcinoma in situ to provide a new therapeutic path.

A clinical trial of 77 adults evaluated the efficacy of Anktiva combined with Bacillus Calmette-Guérin. The study recorded a 62% complete response rate, with 58% of responders maintaining that status at 12 months and 40% at 24 months.

The players

Altor BioScience LLC

The pharmaceutical developer of Anktiva, focused on advanced immunotherapy and cytokine-based treatments.

FDA

The federal agency responsible for regulating drug safety and approving new indications for cancer therapies.

The details

Anktiva, also known as nogapendekin alfa inbakicept-pmln, is an immunotherapy agent delivered directly into the bladder via catheter. It is administered alongside Bacillus Calmette-Guérin once a week for six weeks to stimulate an immune response against the finger-like tumor projections. Depending on the patient's cancer response, this regimen may continue for up to 37 months.

October 29, 2026: The FDA officially announced the expanded approval for Anktiva.

Health Landscape

This approval expands the options available for treating high-grade papillary bladder tumors that no longer respond to traditional BCG therapy. It follows the FDA's broader effort to define development standards for therapies aimed at BCG-unresponsive non-muscle invasive bladder cancer.

Patients diagnosed with high-grade papillary-only non-muscle invasive bladder cancer should consult with their urologist to see if this immunotherapy is a viable option. It is important to discuss the potential for side effects such as urinary pain, urgency, and fever before beginning the six-week induction course.

The takeaway

Anktiva offers a new, non-surgical treatment path for high-grade bladder cancer that has failed to respond to standard BCG therapy. If you are managing this condition, discuss the results of recent clinical trials and your treatment goals with your physician to understand if this therapy is appropriate for you.